CL2017001873A1 - Métodos de purificación de cannabinoides, composiciones y kits de los mismos - Google Patents

Métodos de purificación de cannabinoides, composiciones y kits de los mismos

Info

Publication number
CL2017001873A1
CL2017001873A1 CL2017001873A CL2017001873A CL2017001873A1 CL 2017001873 A1 CL2017001873 A1 CL 2017001873A1 CL 2017001873 A CL2017001873 A CL 2017001873A CL 2017001873 A CL2017001873 A CL 2017001873A CL 2017001873 A1 CL2017001873 A1 CL 2017001873A1
Authority
CL
Chile
Prior art keywords
compositions
kits
purification methods
cannabinoids
cannabinoid
Prior art date
Application number
CL2017001873A
Other languages
English (en)
Inventor
Roura Xavier Nadal
Original Assignee
Phytoplant Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201562106644P priority Critical
Application filed by Phytoplant Res S L filed Critical Phytoplant Res S L
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55349794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001873(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of CL2017001873A1 publication Critical patent/CL2017001873A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/685Processes comprising at least two steps in series
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/70Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
    • C07C37/84Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/18Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
    • C07C39/19Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/43Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/47Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/19Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups having unsaturation outside the aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Abstract

<p>LA PRESENTE MEMORIA DESCRIPTIVA DESCRIBE MÉTODOS PARA LA PURIFICACIÓN DE UNO O MÁS CANNABINOIDES A PARTIR DE MATERIAL VEGETAL, LOS CANNABINOIDES PURIFICADOS Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UNO O MÁS CANNABINOIDES PRODUCIDOS POR EL MÉTODO, Y UTILIZA MÉTODOS DESCRITOS PARA TRATAR UNA ENFERMEDAD O DOLENCIA, EMPLEANDO TALES CANNABINOIDES PURIFICADOS Y COMPOSICIONES FARMACÉUTICAS.</p>
CL2017001873A 2015-01-22 2017-07-20 Métodos de purificación de cannabinoides, composiciones y kits de los mismos CL2017001873A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201562106644P true 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
CL2017001873A1 true CL2017001873A1 (es) 2018-04-13

Family

ID=55349794

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001873A CL2017001873A1 (es) 2015-01-22 2017-07-20 Métodos de purificación de cannabinoides, composiciones y kits de los mismos

Country Status (19)

Country Link
US (1) US9765000B2 (es)
EP (2) EP3247371B1 (es)
JP (1) JP6342587B2 (es)
CN (2) CN107567435B (es)
AU (1) AU2016210070A1 (es)
BR (2) BR112017015536B1 (es)
CA (1) CA2977421A1 (es)
CL (1) CL2017001873A1 (es)
CO (1) CO2017008437A2 (es)
DK (1) DK3247371T3 (es)
ES (1) ES2801005T3 (es)
HK (1) HK1246663A1 (es)
IL (1) IL253576A (es)
MX (1) MX364559B (es)
PE (1) PE20171108A1 (es)
PT (1) PT3247371T (es)
SI (1) SI3247371T1 (es)
UY (2) UY36530A (es)
WO (1) WO2016116628A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111788171A (zh) 2018-01-29 2020-10-16 菲拓普兰特研究公司 使用液:液色谱法纯化大麻素的方法
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
BG112018A (bg) * 2015-05-22 2016-11-30 "Побелч-Гле" Оод Метод за получаване на канабиноиден извлек от коноп
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018145213A1 (en) * 2017-02-09 2018-08-16 Bodhi Research & Development Inc. Cannabinoid-containing fatty acid formulations for treating disorders of the nervous system
WO2018165740A1 (en) * 2017-03-16 2018-09-20 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
IT201700085508A1 (it) * 2017-07-26 2019-01-26 Inalco S R L Metodo per la produzione di cannabinoidi da varietà di canapa industriale
US10814338B2 (en) 2017-08-09 2020-10-27 Delta Separations, Llc Device, system and methods for separation and purification of organic compounds from botanical material
US10851076B2 (en) 2017-08-10 2020-12-01 Pratt Bethers Method for purifying crystals using solvent vapors
EP3449992A1 (en) * 2017-09-04 2019-03-06 Bionorica Ethics GmbH Recovery of acidic cannabinoids from plant material
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
US10941102B2 (en) * 2017-11-29 2021-03-09 Robert Henry Wohleb Aqueous leaching method to produce microcrystalline powder
WO2019126872A1 (en) * 2017-12-27 2019-07-04 CannScience Innovations Inc. Sublingual formulations comprising cannabis resin, methods for making same and uses thereof
US20190201347A1 (en) * 2017-12-29 2019-07-04 TGC Network LLC Cannabidiol Dosage Form
US10463986B2 (en) * 2018-02-07 2019-11-05 Metagreen Ventures Extraction of organic products from plant and animal materials
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020081108A1 (en) * 2018-10-18 2020-04-23 Taba Ip, Llc Purification of cannabinoids from crude cannabis oil
US10610805B1 (en) * 2018-12-10 2020-04-07 Natural Extraction Systems, LLC Methods to separate cannabidiol and tetrahydrocannabinol
WO2020180759A1 (en) * 2019-03-02 2020-09-10 Martha Knight Cannabinoid separation by countercurrent chromatography
CN110304993A (zh) * 2019-05-23 2019-10-08 朱法科 色谱生产高纯度大麻二酚的方法
WO2020248076A1 (en) * 2019-06-12 2020-12-17 Nectar Health Sciences Inc. Methods for extraction, processing, and purification of a selected family of target compounds from cannabis
WO2020252369A1 (en) * 2019-06-14 2020-12-17 Purisys Llc Crystalline cannabigerol
CN110283048B (zh) * 2019-06-28 2020-09-11 云南翰谷生物科技有限公司 大麻二酚晶体的制备方法
WO2021012047A1 (en) * 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a tubular flow reactor
WO2021046303A1 (en) * 2019-09-06 2021-03-11 Ebers Tech Inc. Cannabigerol proline cocrystals
CN110590511B (zh) * 2019-09-11 2021-05-28 上海同田生物技术股份有限公司 一种同时分离次大麻二酚和大麻萜酚的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
SI1536810T1 (sl) * 2002-08-14 2013-02-28 Gw Pharma Limited Ekstrakcija farmacevtsko aktivnih kanabinoidov iz rastlinskih snovi
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
EP2044935B1 (en) * 2007-10-02 2011-01-05 Vivacell Biotechnology Espana S.L. A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
DK2760444T3 (da) * 2011-09-29 2020-07-27 Thc Pharm Gmbh The Health Concept Cannabinoidcarboxylsyrer, salte af cannabinoidcarboxylsyrer, fremstilling og anvendelse deraf

Also Published As

Publication number Publication date
US20160214920A1 (en) 2016-07-28
EP3556376A1 (en) 2019-10-23
UY39011A (es) 2021-02-26
BR112017015536B1 (pt) 2021-05-18
UY36530A (es) 2016-08-31
MX2017009561A (es) 2018-06-20
CN107567435B (zh) 2019-08-09
BR112017015536A2 (pt) 2018-04-17
CA2977421A1 (en) 2016-07-28
CN110563574A (zh) 2019-12-13
MX364559B (es) 2019-04-30
SI3247371T1 (sl) 2020-08-31
IL253576D0 (en) 2017-08-31
DK3247371T3 (da) 2020-06-15
CN107567435A (zh) 2018-01-09
PE20171108A1 (es) 2017-08-07
ES2801005T3 (es) 2021-01-07
HK1246663A1 (zh) 2018-09-14
JP2018504407A (ja) 2018-02-15
US9765000B2 (en) 2017-09-19
BR122019001241B1 (pt) 2021-05-04
EP3247371A1 (en) 2017-11-29
EP3247371B1 (en) 2020-04-01
IL253576A (en) 2018-11-29
CO2017008437A2 (es) 2018-01-05
PT3247371T (pt) 2020-07-02
WO2016116628A1 (en) 2016-07-28
JP6342587B2 (ja) 2018-06-13
AU2016210070A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
CL2017001873A1 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
DK3448859T3 (da) Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2016001911A1 (es) Compuesto heterocíclico fusionado
CL2014001065A1 (es) Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CL2017002606A1 (es) Inhibidor de bromodominio
CL2017001046A1 (es) Inhibidoes del bromodominio
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
CL2016003263A1 (es) Composiciones enriquecidas esteroquímicamente para la liberación de ácidos nucléicos.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
BR112018072663A2 (pt) moduladores da via integrada ao estresse
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
CL2016001367A1 (es) Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).
CL2016001963A1 (es) Heteroarilos inhibidores de syk
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
CL2017000151A1 (es) Derivados de piridona
CO2018008304A2 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo